Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA ≥9 Log10 Copies/Ml)

被引：0
|
作者：
Gordon, Stuart C.
Marcellin, Patrick
Krastev, Zahary
Horban, Andrzej
Petersen, Joerg
Sperl, Jan
Phillip Dinh
Martins, Eduardo B.
Yee, Leland J.
Flaherty, John F.
Kitrinos, Kathryn M.
Rustgi, Nika Berger Vinod K.
Heathcote, Jenny
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S954 / S954
页数：1
相关论文
共 50 条
  • [31] Circulating Tregs Correlate with Viral Load Reduction in Chronic HBV-Treated Patients with Tenofovir Disoproxil Fumarate
    TrehanPati, Nirupma
    Kotillil, Shyam
    Hissar, Syed S.
    Shrivastava, Shikha
    Khanam, Arshi
    Sukriti, Sukriti
    Mishra, Siddartha K.
    Sarin, Shiv Kumar
    JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (03) : 509 - 520
  • [32] MAINTENANCE OF HIGH LEVELS OF VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE (TAF) RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS IN 2 ONGOING PHASE 3 STUDIES
    Chan, Henry Lik Yuen
    Ferret, Maria Asuncion Buti
    Agarwal, Kosh
    Marcellin, Patrick
    Lim, Young-Suk
    Brunetto, Maurizia R.
    Chuang, Wan-Long
    Janssen, Harry L. A.
    Fung, Scott K.
    Izumi, Namiki
    Flaherty, John F.
    Suri, Vithika
    Gao, Bing
    Camus, Gregory
    Gaggar, Anuj
    Brainard, Diana M.
    Pan, Calvin
    Shalimar
    Seto, Wai-Kay
    Gane, Edward J.
    HEPATOLOGY, 2020, 72 : 490A - 490A
  • [33] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
    Buti, Maria
    Stepanova, Tatjana
    Celen, Mustafa K.
    Flisiak, Robert
    Ryder, Stephen D.
    Streinu-Cercel, Adrian
    Gurel, Selim
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Mo, Shuyuan
    Subramanian, Mani
    Nurmukhametova, Elena
    Zoulim, Fabien
    Andreone, Pietro
    Marcellin, Patrick
    HEPATOLOGY, 2017, 66 : 488A - 488A
  • [34] A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B
    Wang, Huan
    Wu, Liping
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (10) : 2390 - 2394
  • [35] THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102); PRELIMINARY ANALYSIS
    Marcellin, Patrick
    Buti, Maria
    Krastev, Zahary
    Germanidis, George
    Kaita, Kelly D.
    Kotzev, Iskren
    Buggisch, Peter
    Weilert, Frank
    Trinh, Huy N.
    Gurel, Selim
    Heathcote, E. Jenny
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    HEPATOLOGY, 2009, 50 (04) : 532A - 533A
  • [36] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
    Janssen, H.
    Gane, E.
    Seto, W-K
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Horban, A.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J.
    Kao, J-H
    Brunetto, M.
    Ferret, M. B.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
  • [37] The Comparison of tenofovir alafenamide fumarate with tenofovir disoproxil fumarate in preventing hepatitis B transmission in mothers with high viral load: a retrospective cohort study
    Zhu, Yunxia
    Wang, Jinhua
    Wang, Ming
    Zhou, Xin
    Zhang, Shuangxia
    Zhang, Shujie
    Yang, Bo
    Yang, Ping
    Hu, Zhongjie
    JOURNAL OF HEPATOLOGY, 2022, 77 : S272 - S272
  • [38] CHARACTERIZATION OF HBSAG KINETICS AND HBSAG SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Marcellin, Patrick
    Heathcote, E. Jenny
    Buti, Maria
    Krastev, Zahary
    Jacobson, Ira M.
    de Man, Robert A.
    Dusheiko, Geoffrey M.
    Zeuzem, Stefan
    Barnes, Chris N.
    Lou, Lillian
    HEPATOLOGY, 2011, 54 : 1036A - 1036A
  • [39] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
    Gane, Edward
    Seto, Wai Kay
    Janssen, Harry L. A.
    Caruntu, Florin A.
    Kim, Hyung Joon
    Abdurakhmanov, Dzhamal
    Nishiguchi, Shuhei
    Horban, Andrzej
    Bae, Ho
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Oberle, Corinna
    Mo, Shuyuan
    Subramanian, G. Mani
    Kao, Jia-Horng
    Brunetto, Maurizia
    Buti, Maria
    SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
  • [40] Factors associated with regression of cirrhosis in patients with chronic hepatitis B (CHB) infection treated with tenofovir disoproxil fumarate (TDF)
    Gane, Ed
    Afdhal, Nezam
    Buti, Maria
    Elsome, Amanda M.
    Flaherty, John F.
    Martins, Eduardo
    Bekele, Neby
    Bornstein, Jeffrey D.
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 164 - 164
12345